Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Alcoholic liver disease: pathogenesis and new therapeutic targets.

Gao B, Bataller R.

Gastroenterology. 2011 Nov;141(5):1572-85. doi: 10.1053/j.gastro.2011.09.002. Epub 2011 Sep 12. Review.

2.

Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice.

Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabé de Angelis M, Schlederer M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM.

Diabetologia. 2011 Aug;54(8):2132-42. doi: 10.1007/s00125-011-2170-0. Epub 2011 May 12.

3.

Fibrosis in alcoholic and nonalcoholic steatohepatitis.

Bataller R, Rombouts K, Altamirano J, Marra F.

Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):231-44. doi: 10.1016/j.bpg.2011.02.010. Review.

PMID:
21497741
4.

Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease.

Lavallard VJ, Bonnafous S, Patouraux S, Saint-Paul MC, Rousseau D, Anty R, Le Marchand-Brustel Y, Tran A, Gual P.

PLoS One. 2011 Mar 18;6(3):e17599. doi: 10.1371/journal.pone.0017599.

5.

Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients.

Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P.

PLoS One. 2010 Oct 22;5(10):e13577. doi: 10.1371/journal.pone.0013577.

6.

Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.

Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whitington PF, Diehl AM.

Hepatology. 2011 Jan;53(1):106-15. doi: 10.1002/hep.23998. Epub 2010 Oct 21.

7.

Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease.

Naveau S, Cassard-Doulcier AM, Njiké-Nakseu M, Bouchet-Delbos L, Barri-Ova N, Boujedidi H, Dauvois B, Balian A, Maitre S, Prévot S, Dagher I, Agostini H, Grangeot-Keros L, Emilie D, Perlemuter G.

J Hepatol. 2010 Jun;52(6):895-902. doi: 10.1016/j.jhep.2010.01.029. Epub 2010 Mar 24.

PMID:
20399524
8.

Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects.

Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S.

Clin Chim Acta. 2010 May 2;411(9-10):675-8. doi: 10.1016/j.cca.2010.01.029. Epub 2010 Feb 2.

PMID:
20138033
9.

Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance.

Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Säemann MD, Geyeregger R, Schlederer M, Kenner L, Stulnig TM.

Diabetes. 2010 Apr;59(4):935-46. doi: 10.2337/db09-0404. Epub 2010 Jan 27.

10.

Alcoholic hepatitis.

Lucey MR, Mathurin P, Morgan TR.

N Engl J Med. 2009 Jun 25;360(26):2758-69. doi: 10.1056/NEJMra0805786. Review. No abstract available.

PMID:
19553649
11.

Predictive factors for pure steatosis in alcoholic patients.

Naveau S, Thaury J, Barri-Ova N, Balian A, Dauvois B, Njiké-Nakseu M, Prévot S, Agostini H, Perlemuter G.

Alcohol Clin Exp Res. 2009 Jun;33(6):1104-10. doi: 10.1111/j.1530-0277.2009.00932.x. Epub 2009 Mar 23.

PMID:
19382900
12.

Liver biopsy.

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases.

Hepatology. 2009 Mar;49(3):1017-44. doi: 10.1002/hep.22742. No abstract available.

PMID:
19243014
13.

Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.

Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M, Balian A, Njiké-Nakseu M, Perlemuter G, Poynard T.

Hepatology. 2009 Jan;49(1):97-105. doi: 10.1002/hep.22576.

PMID:
19053048
14.

Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.

Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX.

Hepatology. 2008 Dec;48(6):1834-42. doi: 10.1002/hep.22531.

PMID:
18972404
15.

Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity.

Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, Dahman M, Tordjman J, Clément K, McQuaid SE, Frayn KN, Huet PM, Gugenheim J, Lotersztajn S, Le Marchand-Brustel Y, Tran A, Gual P.

Diabetes. 2009 Jan;58(1):125-33. doi: 10.2337/db08-0400. Epub 2008 Oct 24.

16.

Interaction of osteopontin with neutrophil alpha(4)beta(1) and alpha(9)beta(1) integrins in a rodent model of alcoholic liver disease.

Banerjee A, Lee JH, Ramaiah SK.

Toxicol Appl Pharmacol. 2008 Dec 1;233(2):238-46. doi: 10.1016/j.taap.2008.08.008. Epub 2008 Aug 22.

PMID:
18778724
17.

Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.

Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL.

Aliment Pharmacol Ther. 2008 Nov 15;28(10):1188-98. doi: 10.1111/j.1365-2036.2008.03831.x. Epub 2008 Aug 14.

18.

Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis.

Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, Li K, Tong X, Dai J, Yao S, Wu M, Guo Y.

Gastroenterology. 2008 Sep;135(3):956-68. doi: 10.1053/j.gastro.2008.05.025. Epub 2008 May 7.

PMID:
18555021
19.

Diagnosis and quantitation of fibrosis.

Manning DS, Afdhal NH.

Gastroenterology. 2008 May;134(6):1670-81. doi: 10.1053/j.gastro.2008.03.001. Review.

PMID:
18471546
20.

Mechanisms of hepatic fibrogenesis.

Friedman SL.

Gastroenterology. 2008 May;134(6):1655-69. doi: 10.1053/j.gastro.2008.03.003. Review.

Supplemental Content

Support Center